Description

Simple

An antibiotic available in a combination product called Synercid that is used to treat severe infections that cannot be treated with an antibiotic called vancomycin, and severe skin infections.

Clinical

An antibiotic used with quinupristin to treat severe or life-threatening infections of vancomycin-resistant Enterococcus faecium (VREF), and skin infections caused by methicillin susceptible staphylococcus aureus or streptococcus pyogenes.

Overview

Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.

Pharmacology

Indication

For the treatment of bacterial infections (usually in combination with quinupristin).

Pharmacodynamic

Dalfopristin is a streptogramin antibiotic, derived from pristinamycin IIA.

Mechanism of action

The site of action of dalfopristin is the bacterial ribosome. Dalfopristin
has been shown to inhibit the early phase of protein synthesis.

Absorption

Information currently not available.

Protein binding

Moderate

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

The elimination half-life is approximately 0.70 hours.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Dalfopristin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Dalfopristin.
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Dalfopristin.
4-hydroxycoumarin
The metabolism of 4-hydroxycoumarin can be decreased when combined with Dalfopristin.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be decreased when combined with Dalfopristin.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Dalfopristin.
Albendazole
The metabolism of Albendazole can be decreased when combined with Dalfopristin.
Alfentanil
The metabolism of Alfentanil can be decreased when combined with Dalfopristin.
Alfuzosin
The metabolism of Alfuzosin can be decreased when combined with Dalfopristin.
Allylestrenol
The metabolism of Allylestrenol can be decreased when combined with Dalfopristin.
Alpelisib
The metabolism of Alpelisib can be decreased when combined with Dalfopristin.
Alprazolam
The metabolism of Alprazolam can be decreased when combined with Dalfopristin.
Aminophylline
The metabolism of Aminophylline can be decreased when combined with Dalfopristin.
Amiodarone
The metabolism of Amiodarone can be decreased when combined with Dalfopristin.
Aripiprazole
The metabolism of Aripiprazole can be decreased when combined with Dalfopristin.
Aripiprazole lauroxil
The metabolism of Aripiprazole lauroxil can be decreased when combined with Dalfopristin.
Artesunate
The metabolism of Artesunate can be decreased when combined with Dalfopristin.
Astemizole
The metabolism of Astemizole can be decreased when combined with Dalfopristin.
Atazanavir
The metabolism of Atazanavir can be decreased when combined with Dalfopristin.
Atorvastatin
The metabolism of Atorvastatin can be decreased when combined with Dalfopristin.
Azithromycin
The metabolism of Azithromycin can be decreased when combined with Dalfopristin.
4 References
  1. 1 . Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44.PubMed: 11219478
  2. 2 . Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97.PubMed: 10651391
  3. 3 . Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6.PubMed: 11764864
  4. 4 . Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17.PubMed: 11190346